XTSEBU
Market cap15mUSD
Dec 24, Last price
0.08CAD
1D
0.00%
1Q
-48.39%
Jan 2017
-96.92%
Name
Burcon NutraScience Corp
Chart & Performance
Profile
Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company's products include Peazazz, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products; and Peazac and Peazac 850, a pea protein for plant-based meat alternative products, ready-to-mix powders, ready-to-mix beverages, dairy alternatives, and nutrition bars, as well as other applications requiring the most neutral flavor and moderate viscosity. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS and Nutratein-TZ, a blend of Peazac pea protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and other foods and nutritional products. Further, it provides MeritPro, a nutritional protein blend, including allergen-free, gluten-free, non-dairy, non-GMO, and vegan. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
Income | ||||||||||
Revenues | 184 -49.34% | 364 112.23% | 171 -33.70% | |||||||
Cost of revenue | 7,775 | 7,395 | 7,255 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (7,590) | (7,031) | (7,084) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 78 | 5,500 | 4,295 | |||||||
Tax Rate | ||||||||||
NOPAT | (7,668) | (12,531) | (11,379) | |||||||
Net income | (7,446) -70.64% | (25,364) 147.25% | (10,258) 1,561.30% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 7,671 | 272 | ||||||||
BB yield | -21.42% | -0.21% | ||||||||
Debt | ||||||||||
Debt current | 261 | 34 | 14 | |||||||
Long-term debt | 6,666 | 5,161 | 117 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 2,729 | 3,739 | (20,394) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (5,777) | (5,983) | (5,877) | |||||||
CAPEX | (127) | (360) | (1,269) | |||||||
Cash from investing activities | (39) | (4,467) | (1,269) | |||||||
Cash from financing activities | 8,565 | 4,896 | 174 | |||||||
FCF | (7,781) | (12,656) | (11,232) | |||||||
Balance | ||||||||||
Cash | 4,197 | 1,457 | 7,124 | |||||||
Long term investments | 13,403 | |||||||||
Excess cash | 4,188 | 1,439 | 20,518 | |||||||
Stockholders' equity | (12,130) | (12,627) | 12,384 | |||||||
Invested Capital | 23,950 | 21,935 | 15,937 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 121,398 | 108,729 | 108,588 | |||||||
Price | 0.30 9.26% | 0.27 -77.31% | 1.19 -74.57% | |||||||
Market cap | 35,813 21.99% | 29,357 -77.28% | 129,220 -73.16% | |||||||
EV | 38,542 | 33,095 | 108,826 | |||||||
EBITDA | (6,890) | (6,370) | (6,811) | |||||||
EV/EBITDA | ||||||||||
Interest | 512 | 299 | 113 | |||||||
Interest/NOPBT |